Optimi Health appoints Chief Clinical Development Officer
Optimi Health Corp. appointed Dr. Michael Blough as Chief Clinical Development Officer, overseeing planned Phase 2 psilocybin and Phase 3 MDMA trials expected to begin enrolling next year.
Optimi Health Corp. appointed Dr. Michael Blough as Chief Clinical Development Officer, overseeing planned Phase 2 psilocybin and Phase 3 MDMA trials expected to begin enrolling next year.